Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Apidra 100 Units/ml solution for injection in a vial

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Insulin glulisine may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Insulin glulisine

Equivalent medicines (same active substance, strength and form)

Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What it is and what it is used for

for Apidra is an antidiabetic agent, used to reduce high blood sugar in patients with diabetes mellitus; it may be given to adults, adolescents and children, 6 years of age and older. Diabetes mellitus is a disease where your body does not produce enough insulin to control the level of blood sugar. It is made by biotechnology. It has a rapid onset within 10-20 minutes and a short duration, about 4 hours.

What you need to know before you take it

e Apidra Do not use Apidra

  • If you are allergic to insulin glulisine or any of the other ingredients of this medicine (listed in section 6).
  • If your blood sugar is too low (hypoglycaemia), follow the guidance for hypoglycaemia (see box at the end of this leaflet). Warnings and precautions Talk to your doctor, pharmacist or nurse before using Apidra. Follow closely the instructions for dose, monitoring (blood tests), diet and physical activity (physical work and exercise) as discussed with your doctor.

Special patient groups If you have liver or kidney problems, speak to your doctor as you may need a lower dose. There is insufficient clinical information on the use of Apidra in children younger than the age of 6 years. Skin changes at the injection site The injection site should be rotated to prevent skin changes such as lumps under the skin. The insulin may not work very well if you inject into a lumpy area (see How to use Apidra). Contact your doctor if you are currently injecting into a lumpy area before you start injecting in a different area. Your doctor may tell you to check your blood sugar more closely, and to adjust your insulin or your other antidiabetic medications dose. Travel Before travelling consult your doctor. You may need to talk about

  • the availability of your insulin in the country you are visiting,
  • supplies of insulin, injection syringes etc,
  • correct storage of your insulin while travelling,
  • timing of meals and insulin administration while travelling,
  • the possible effects of changing to different time zones,
  • possible new health risks in the countries to be visited,
  • what you should do in emergency situations when you feel unwell or become ill. Illnesses and injuries In the following situations, the management of your diabetes may require extra care:
  • If you are ill or have a major injury then your blood sugar level may increase (hyperglycaemia).
  • If you are not eating enough your blood sugar level may become too low (hypoglycaemia). In most cases you will need a doctor. Make sure that you contact a doctor early. If you have type 1 diabetes (insulin dependent diabetes mellitus), do not stop your insulin and continue to get enough carbohydrates. Always tell people who are caring for you or treating you that you require insulin. Some patients with long-standing type 2 diabetes mellitus and heart disease or previous stroke who were treated with pioglitazone and insulin experienced the development of heart failure. Inform your doctor as soon as possible if you experience signs of heart failure such as unusual shortness of breath or rapid increase in weight or localised swelling (oedema). Other medicines and Apidra Some medicines cause changes in the blood sugar level (decrease, increase or both depending on the situation). In each case, it may be necessary to adjust your insulin dose to avoid blood sugar levels that are either too low or too high. Be careful when you start or stop taking another medicine. Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Before taking a medicine ask your doctor if it can affect your blood sugar level and what action, if any, you need to take.

Medicines that may cause your blood sugar level to fall (hypoglycaemia) include:

  • all other medicines to treat diabetes,
  • angiotensin converting enzyme (ACE) inhibitors (used to treat certain heart conditions or high blood pressure),
  • disopyramide (used to treat certain heart conditions),
  • fluoxetine (used to treat depression),
  • fibrates (used to lower high levels of blood lipids),
  • monoamine oxidase (MAO) inhibitors (used to treat depression),
  • pentoxifylline, propoxyphene, salicylates (such as aspirin, used to relieve pain and lower fever),
  • sulphonamide antibiotics. Medicines that may cause your blood sugar level to rise (hyperglycaemia) include:
  • corticosteroids (such as "cortisone" used to treat inflammation),
  • danazol (medicine acting on ovulation),
  • diazoxide (used to treat high blood pressure),
  • diuretics (used to treat high blood pressure or excessive fluid retention),
  • glucagon (pancreas hormone used to treat severe hypoglycaemia),
  • isoniazid (used to treat tuberculosis),
  • oestrogens and progestogens (such as in the contraceptive pill used for birth control),
  • phenothiazine derivatives (used to treat psychiatric disorders),
  • somatropin (growth hormone),
  • sympathomimetic medicines (such as epinephrine [adrenaline], salbutamol, terbutaline used to treat asthma),
  • thyroid hormones (used to treat thyroid gland disorders),
  • protease inhibitors (used to treat HIV),
  • atypical antipsychotic medicines (such as olanzapine and clozapine). Your blood sugar level may either rise or fall if you take:
  • beta-blockers (used to treat high blood pressure),
  • clonidine (used to treat high blood pressure),
  • lithium salts (used to treat psychiatric disorders). Pentamidine (used to treat some infections caused by parasites) may cause hypoglycaemia which may sometimes be followed by hyperglycaemia. Beta-blockers like other sympatholytic medicines (such as clonidine, guanethidine and reserpine) may weaken or suppress entirely the first warning symptoms which help you to recognise a hypoglycaemia. If you are not sure whether you are taking one of those medicines ask your doctor or pharmacist. Apidra with alcohol Your blood sugar levels may either rise or fall if you drink alcohol. Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Inform your doctor if you are planning to become pregnant, or if you are already pregnant. Your insulin dose may need to be changed during pregnancy and after giving birth. Careful control of your diabetes, and prevention of hypoglycaemia, is important for the health of your baby.

There are no or limited data on the use of Apidra in pregnant women. If you are breast-feeding consult your doctor as you may require adjustments in your insulin doses and your diet. Driving and using machines Your ability to concentrate or react may be reduced if:

  • you have hypoglycaemia (low blood sugar levels),
  • you have hyperglycaemia (high blood sugar levels). Keep this possible problem in mind in all situations where you might put yourself and others at risk (such as driving a car or using machines). You should contact your doctor for advice on driving if:
  • you have frequent episodes of hypoglycaemia,
  • the first warning symptoms which help you to recognise hypoglycaemia are reduced or absent. Important information about some of the ingredients of Apidra This medicine contains less than 1 mmol (23 mg) sodium per dose, i.e. it is essentially 'sodium-free'. Apidra contains metacresol Apidra contains metacresol, which may cause allergic reactions.

How to take it

Apidra Dose Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. Based on your life-style and the results of your blood sugar (glucose) tests and your previous insulin usage, your doctor will determine how much Apidra you will need. Apidra is a short-acting insulin. Your doctor may tell you to use it in combination with an intermediate, long-acting insulin, a basal insulin or with tablets used to treat high blood sugar levels. If you switch from another insulin to insulin glulisine, your dosage may have to be adjusted by your doctor. Many factors may influence your blood sugar level. You should know these factors so that you are able to react correctly to changes in your blood sugar level and to prevent it from becoming too high or too low. See the box at the end of this leaflet for further information. Method of administration Apidra is injected under the skin (subcutaneously). It may also be given intravenously by healthcare professionals under close supervision by a doctor. Your doctor will show you in which area of the skin you should inject Apidra. Apidra can be injected in the abdominal wall, the thigh or upper arm or by continuous infusion in the abdominal wall. The effect will be slightly quicker if the insulin is injected into your abdomen. As for all insulins, injection sites and infusion sites within an injection area (abdomen, thigh or upper arm) must be rotated from one injection to the next. Frequency of administration Apidra should be taken shortly (0-15 minutes) before or soon after meals.

Used font: Ocean Sans Pro San

Legende / Legend SAP-Nr. / Plant PM code: Sprachvariante / Country code: Version: Datum / Date: DMC-Inhalt / DMC content:

958647 028 2 02.04.2026 RP02 <MAT>958647

Abmessungen / Dimensions: Schriftgröße / Font size: Zeilenabstand / Line spacing: Seite / Page:

296 × 420 mm 9,5 Pt 9,5 Pt 1/2

Druckbare Farben / Printing colours

Technische Information / Technical information

Pantone Black C

Kontur / Outline

<MAT>958647

Instructions for proper use How to handle the vials Apidra vials are for use with insulin syringes with the corresponding unit scale and for use with an insulin pump system. Look at the vial before you use it. Only use it if the solution is clear, colourless and has no visible particles in it. Do not shake or mix it before use. Always use a new vial if you notice that your blood sugar control is unexpectedly getting worse. This is because the insulin may have lost some of its effectiveness. If you think you may have a problem with Apidra, have it checked by your doctor or pharmacist. If you have to mix two types of insulin Apidra must not be mixed with any preparation other than NPH human insulin. If Apidra is mixed with NPH human insulin, Apidra should be drawn into the syringe first. Injection should be given immediately after mixing. How to handle an infusion pump system Before using Apidra in the pump system you should have been given detailed instructions on how to use the pump system. In addition, you should have been provided with information about what to do if you become ill or if your blood sugar levels get too high or too low, or if the pump system fails. Use the pump system recommended by your doctor. Read and follow the instructions that come with your insulin infusion pump. Follow your doctor's instructions about the basal infusion rate and the mealtime insulin boluses to be taken. Measure your blood sugar level regularly to make sure you get the benefit of the insulin infusion and to make sure that the pump is working properly. Change the infusion set and reservoir at least every 48 hours using aseptic technique. These instructions may differ from the instructions that come with your insulin infusion pump. When you use Apidra in the pump system, it is important that you always follow these specific instructions. Failure to follow these specific instructions may lead to serious adverse events. Apidra must never be mixed with diluents or any other insulin when used in a pump. What to do if the pump system fails or when the pump is used incorrectly Pump or infusion set problems or using the pump incorrectly can result in you not getting enough insulin. This can quickly cause you to have high blood sugar and diabetic ketoacidosis (build-up of acid in the blood because the body is breaking down fat instead of sugar). If your blood sugar level starts to rise, contact your doctor, pharmacist or nurse as soon as possible. They will tell you what needs to be done. You may need to use Apidra with syringes or pens. You should always have an alternative insulin delivery system available for injection under the skin in case the pump system fails. If you use more Apidra than you should

  • If you have injected too much Apidra, your blood sugar level may become too low (hypoglycaemia). Check your blood sugar frequently. In general, to prevent hypoglycaemia you must eat more food and monitor your blood sugar. For information on the treatment of hypoglycaemia, see box at the end of this leaflet.

If you forget to use Apidra

  • If you have missed a dose of Apidra or if you have not injected enough insulin, your blood sugar level may become too high (hyperglycaemia). Check your blood sugar frequently. For information on the treatment of hyperglycaemia, see box at the end of this leaflet.
  • Do not take a double dose to make up for a forgotten dose. If you stop using Apidra This could lead to severe hyperglycaemia (very high blood sugar) and ketoacidosis (build-up of acid in the blood because the body is breaking down fat instead of sugar). Do not stop Apidra without speaking to a doctor, who will tell you what needs to be done. If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse. Insulin Mix-ups You must always check the insulin label before each injection to avoid mix-ups between Apidra and other insulins. 4. Possible side effects Like all medicines, this medicine can cause side effects, although not everybody gets them. Serious side effects

Hypoglycaemia (low blood sugar) can be very serious. Hypoglycaemia is a very

commonly reported side effect (may affect more than 1 in 10 people). Hypoglycaemia (low blood sugar) means that there is not enough sugar in the blood. If your blood

sugar level falls too much you may become unconscious. Serious hypoglycaemia may cause brain damage and may be lifethreatening. If you have symptoms of low blood sugar, take actions to increase your blood sugar level immediately. See the box at the end of this leaflet for important further information about hypoglycaemia and its treatment. If you experience the following symptoms, contact your doctor immediately: Systemic allergic reactions are side effects reported uncommonly (may affect up to 1 in 100 people). Generalised allergy to insulin: Associated symptoms may include large-scale skin reactions (rash and itching all over the body), severe swelling of skin or mucous membranes (angioedema), shortness of breath, a fall in blood pressure with rapid heartbeat and sweating. These could be symptoms of severe cases of generalised

allergy to insulin, including anaphylactic reaction, which may be life-threatening.

Hyperglycaemia (high blood sugar) means that there is too much sugar in the blood. The frequency of hyperglycaemia cannot be estimated. If your blood sugar level is too high, this tells you that you may need more insulin than you have injected. Hyperglycaemia can cause diabetic ketoacidosis (build-up of acid in the blood because the body is breaking down fat instead of sugar). These are serious side effects.

958647-R

These conditions can happen when there are problems with the infusion pump or when the pump system is used incorrectly. This means you may not always get enough insulin to treat your diabetes. If this happens you must seek urgent medical help. Always have available an alternative insulin delivery system for injection under the skin (see section 3 under "How to

Possible side effects

not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

This leaflet does not contain all the information about your medicine. If you have any questions or are not sure about anything, ask your doctor or pharmacist. This leaflet was last revised in April 2026

HYPERGLYCAEMIA AND HYPOGLYCAEMIA

Always carry some sugar (at least 20 grams) with you. Carry some information with you to show you are a person with diabetes. HYPERGLYCAEMIA (high blood sugar levels) If your blood sugar is too high (hyperglycaemia), you may not have injected enough insulin. Why does hyperglycaemia occur?

Examples include:

  • you have not injected your insulin or not injected enough, or if it has become less effective, for example through incorrect storage,
  • you are doing less exercise than usual, you are under stress (emotional distress, excitement), or you have an injury, operation, infection or fever,
  • you are taking or have taken certain other medicines (see section 2, "Other medicines and Apidra"). Warning symptoms of hyperglycaemia Thirst, increased need to urinate, tiredness, dry skin, reddening of the face, loss of appetite, low blood pressure, fast heartbeat, and glucose and ketone bodies in urine. Stomach pain, fast and deep breathing, sleepiness or even loss of consciousness may be signs of a serious condition (ketoacidosis) resulting from lack of insulin.

What Apidra contains

  • The active substance is insulin glulisine. Each ml of the solution contains 100 Units of insulin glulisine (equivalent to 3.49 mg). Each vial contains 10 ml of solution for injection, equivalent to 1000 Units.
  • The other ingredients are: metacresol (see section 2 under "Apidra contains metacresol"), sodium chloride (see section 2 under "Important information about some of the ingredients of Apidra"), trometamol, polysorbate 20, concentrated hydrochloric acid, sodium hydroxide, water for injections.

What should you do if you experience hyperglycaemia? Test your blood sugar level and your urine for ketones as soon as any of the above symptoms occur. Severe

hyperglycaemia or ketoacidosis must always be treated by a doctor, normally in a hospital. HYPOGLYCAEMIA

(low blood sugar levels)

If your blood sugar level falls too much you may become unconscious. Serious hypoglycaemia may cause a heart attack or brain damage and may be life-threatening. You normally should be able to recognise when your blood sugar is falling too much so that you can take the right actions.

What Apidra looks like and contents of the pack Apidra 100 Units/ml solution for injection in a vial is a clear, colourless, aqueous solution with no particles visible. Each vial contains 10 ml solution (1000 Units). Packs of 1, 2, 4 and 5 vials are available. Not all pack sizes may be marketed.

Why does hypoglycaemia occur? Examples include:

  • you inject too much insulin,
  • you miss meals or delay them,
  • you do not eat enough, or eat food containing less carbohydrate than normal (sugar and substances similar to sugar are called carbohydrates; however, artificial sweeteners are NOT carbohydrates),
  • you lose carbohydrates due to vomiting or diarrhoea,

Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder Sanofi 410 Thames Valley Park Drive Reading Berkshire RG6 1PT UK Tel: 0800 035 2525 Email: [email protected]

Instruction for intravenous administration

958647 028 2 02.04.2026 RP02

Abmessungen / Dimensions: Schriftgröße / Font size: Zeilenabstand / Line spacing: Seite / Page:

296 × 420 mm 9,5 Pt 9,5 Pt 2/2

Warning symptoms of hypoglycaemia

  • In your body Examples of symptoms that tell you that your blood sugar level is falling too much or too fast: sweating, clammy skin, anxiety, fast heartbeat, high blood pressure, palpitations and irregular heartbeat. These symptoms often develop before the symptoms of a low sugar level in the brain.
  • In your brain Examples of symptoms that indicate a low sugar level in the brain: headaches, intense hunger, nausea, vomiting, tiredness, sleepiness, sleep disturbances, restlessness, aggressive behaviour, lapses in concentration, impaired reactions, depression, confusion, speech disturbances (sometimes total loss of speech), visual disorders, trembling, paralysis, tingling sensations (paraesthesia), numbness and tingling sensations in the area of the mouth, dizziness, loss of self-control,
  • inability to look after yourself, convulsions and loss of consciousness. The first symptoms which alert you to hypoglycaemia ("warning symptoms") may change, be weaker or may be missing altogether if:
  • you are elderly,
  • you have had diabetes for a long time,
  • you suffer from a certain type of nervous disease (diabetic autonomic neuropathy),
  • you have recently suffered hypoglycaemia (for example the day before) or if it develops slowly,
  • you have almost normal or, at least, greatly improved blood sugar levels,

What should you do if you experience hypoglycaemia? 1. Do not inject insulin. Immediately take about 10 to 20 g sugar, such as glucose, sugar cubes or a sugar-sweetened beverage. Caution: Artificial sweeteners and foods with artificial sweeteners (such as diet drinks) are of no help in treating hypoglycaemia. 2. Then eat something that has a long-acting effect in raising your blood sugar (such as bread or pasta). Your doctor or nurse should have discussed this with you previously.

3. If the hypoglycaemia comes back again take another 10 to 20 g sugar. 4. Speak to a doctor immediately if you are not able to control the hypoglycaemia or if it recurs. Tell your relatives, friends and close colleagues the following: If you are not able to swallow or if you are unconscious, you will require glucagon (a medicine which increases blood sugar) or an injection of glucose. These treatments are justified even if it is not certain that you have hypoglycaemia. It is advisable to test your blood sugar immediately after taking glucose to check that you really have hypoglycaemia.

Apidra should be used at a concentration of 1 Unit/ml insulin glulisine in infusion systems with sodium chloride 9 mg/ml (0.9%) solution for infusion with or without 40 mmol/l potassium chloride using coextruded polyolefin/polyamide plastic infusion bags with a dedicated infusion line. Insulin glulisine for intravenous use at a concentration of 1 Unit/ml is stable at room temperature for 48 hours. After dilution for intravenous use, the solution should be inspected visually for particulate matter prior to administration. Never use the solution if it has become cloudy or contains particles; use it only if it is clear and colourless. Apidra was found to be incompatible with Glucose 5% solution and Ringer's solution and, therefore, must not be used with these solution fluids. The use of other solutions has not been studied.

Used font: Ocean Sans Pro San

SAP-Nr. / Plant PM code: Sprachvariante / Country code: Version: Datum / Date:

Hypoglycaemia is also more likely to occur if:

  • you have just begun insulin treatment or changed to another insulin preparation,
  • your blood sugar levels are almost normal or are unstable,
  • you change the area of skin where you inject insulin (for example from the thigh to the upper arm),
  • you suffer from severe kidney or liver disease, or some other disease such as hypothyroidism.
  • you are taking or have taken certain other medicines (see section 2, "Other medicines and Apidra). In such a case, you may develop severe hypoglycaemia (and even faint) before you are aware of the problem. Be familiar with your warning symptoms. If necessary, more frequent blood sugar testing can help to identify mild hypoglycaemic episodes that may otherwise be overlooked. If you are not confident about recognising your warning symptoms, avoid situations (such as driving a car) in which you or others would be put at risk by hypoglycaemia.

THE FOLLOWING INFORMATION IS INTENDED FOR HEALTHCARE PROFESSIONALS ONLY: Apidra can be administered intravenously, which should be carried out by healthcare professionals.

Manufacturer Sanofi-Aventis Deutschland GmbH Industriepark Höchst, D-65926 Frankfurt Germany

Legende / Legend

  • you drink alcohol, particularly if you are not eating much,
  • you are doing more exercise than usual or a different type of physical activity,
  • you are recovering from an injury or operation or other stress,
  • you are recovering from an illness or from fever,
  • you are taking or have stopped taking certain other medicines (see section 2, "Other medicines and Apidra").

Druckbare Farben / Printing colours

Technische Information / Technical information

Pantone Black C

Kontur / Outline

How to store it

Apidra Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date, which is stated on the carton and on the label of the vial after "EXP". The expiry date refers to the last day of that month.

handle an infusion pump system" and "What to do if the pump system fails or when the pump is used incorrectly"). For more information on signs and symptoms of hyperglycaemia refer to the box at the end of this leaflet.

Unopened vials Store in a refrigerator (2 °C – 8 °C). Do not freeze. Do not put Apidra next to the freezer compartment or a freezer pack. Keep the vial in the outer carton in order to protect from light.

Other side effects Tell your doctor, pharmacist or nurse if you notice any of the following side effects:

  • Skin changes at the injection site: If you inject insulin too often at the same place, the fatty tissue may either shrink (lipoatrophy) or thicken (lipohypertrophy) (may affect up to 1 in 1,000 people). Lumps under the skin may also be caused by buildup of a protein called amyloid (cutaneous amyloidosis; how often this occurs is not known). The insulin may not work very well if you inject into a lumpy area. Change the injection site with each injection to help prevent these skin changes.

Opened vials Once in use, the vial may be stored for a maximum of 4 weeks in the outer carton below 25 °C away from direct heat or direct light. Do not use the vial after this time period. It is recommended that the date of the first use be noted on the label. Do not use this medicine if it does not appear clear and colourless. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

Common reported side effects (may affect

Contents of the pack and other information

up to 1 in 10 people)

  • Skin and allergic reactions at the injection site. Reactions at the injection site may occur (such as reddening, unusually intense pain on injection, itching, hives, swelling or inflammation). They can also spread around the injection site. Most minor reactions to insulins usually resolve in a few days to a few weeks.

Side effects where the frequency cannot be

estimated from the available data

  • Eye reactions A marked change (improvement or worsening) in your blood sugar control can disturb your vision temporarily. If you have proliferative retinopathy (an eye disease related to diabetes) severe hypoglycaemic attacks may cause temporary loss of vision.

Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any

Frequently asked questions about Apidra 100 Units/ml solution for injection in a vial

How do I take Apidra 100 Units/ml solution for injection in a vial?

Apidra 100 Units/ml solution for injection in a vial comes as injection containing 100iu. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in Apidra 100 Units/ml solution for injection in a vial?

The active substance in Apidra 100 Units/ml solution for injection in a vial is insulin glulisine.

Are there equivalent medicines to Apidra 100 Units/ml solution for injection in a vial?

Medicines with the same active substance, strength and form include: Apidra 100 Units/ml solution for injection in a cartridge, Apidra SoloStar 100 Units/ml solution for injection in a pre-filled pen. They are interchangeable only if your prescriber or pharmacist says so.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Apidra 100 Units/ml solution for injection in a vial, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Apidra 100 Units/ml solution for injection in a vial without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Insulin glulisine (3 medicines)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

Treatment of adults, adolescents and children 6 years or older, with diabetes mellitus, where treatment with insulin is required.

4.2. Posology and method of administration

Posology

The potency of this preparation is stated in units. These units are exclusive to Apidra and are not the same as IU or the units used to express the potency of other insulin analogues (see section 5.1).

Apidra should be used in regimens that include an intermediate or long acting insulin or basal insulin analogue and can be used with oral hypoglycaemic agents.

The dose of Apidra should be individually adjusted.

Special populations

Renal impairment

The pharmacokinetic properties of insulin glulisine are generally maintained in patients with renal impairment. However, insulin requirements may be reduced in the presence of renal impairment (see section 5.2).

Hepatic impairment

The pharmacokinetic properties of insulin glulisine have not been investigated in patients with decreased liver function. In patients with hepatic impairment, insulin requirements may be diminished due to reduced capacity for gluconeogenesis and reduced insulin metabolism.

Elderly

Limited pharmacokinetic data are available in elderly patients with diabetes mellitus. Deterioration of renal function may lead to a decrease in insulin requirements.

Paediatric population

There is insufficient clinical information on the use of Apidra in children younger than the age of 6 years.

Method of administration

Intravenous use

Apidra can be administered intravenously. This should be carried out by healthcare professionals.

Apidra must not be mixed with glucose or Ringer's solution or with any other insulin.

Continuous subcutaneous insulin infusion

Apidra may be used for Continuous Subcutaneous Insulin Infusion (CSII) in pump systems suitable for insulin infusion with the appropriate catheters and reservoirs. Patients using CSII should be comprehensively instructed on the use of the pump system.

The infusion set and reservoir used with Apidra must be changed at least every 48 hours using aseptic technique. These instructions may differ from general pump manual instructions. It is important that patients follow the Apidra specific instructions when using Apidra. Failure to follow Apidra specific instructions may lead to serious adverse events.

When used with a subcutaneous insulin infusion pump, Apidra must not be mixed with diluents or any other insulin.

Patients administering Apidra by CSII must have an alternative insulin delivery system available in case of pump system failure (see section 4.4 and 4.8).

For further details on handling, see section 6.6.

Subcutaneous use

Apidra should be given by subcutaneous injection shortly (0‑15 min) before or soon after meals or by continuous subcutaneous pump infusion.

Apidra should be administered subcutaneously in the abdominal wall, thigh or deltoid or by continuous infusion in the abdominal wall. Injection sites and infusion sites within an injection area (abdomen, thigh or deltoid) should be rotated from one injection to the next in order to reduce the risk of lipodystrophy and cutaneous amyloidosis (see section 4.4 and 4.8).

The rate of absorption, and consequently the onset and duration of action, may be affected by the injection site, exercise and other variables. Subcutaneous injection in the abdominal wall ensures a slightly faster absorption than other injection sites (see section 5.2).

Care should be taken to ensure that a blood vessel has not been entered. After injection, the site of injection should not be massaged. Patients must be educated to use proper injection techniques.

Mixing with insulins

When administered as a subcutaneous injection, Apidra must not be mixed with other medicinal products except NPH human insulin.

For further details on handling, see section 6.6.

Before using SoloStar, the Instructions for use included in the Package leaflet must be read carefully (see section 6.6).

4.3. Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Hypoglycaemia.

4.4. Special warnings and precautions for use

Traceability

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

Transferring a patient to another type or brand of insulin should be done under strict medical supervision. Changes in strength, brand (manufacturer), type (regular, neutral protamine Hagedorn [NPH], lente, long-acting, etc.), origin (animal, human, human insulin analogue) and/or method of manufacture may result in the need for a change in dose. Concomitant oral antidiabetic treatment may need to be adjusted.

Patients must be instructed to perform continuous rotation of the injection site to reduce the risk of developing lipodystrophy and cutaneous amyloidosis. There is a potential risk of delayed insulin absorption and worsened glycaemic control following insulin injections at sites with these reactions. A sudden change in the injection site to an unaffected area has been reported to result in hypoglycaemia. Blood glucose monitoring is recommended after the change in the injection site, and dose adjustment of antidiabetic medications may be considered.

Hyperglycaemia

The use of inadequate doses or discontinuation of treatment, especially in insulin‑dependent diabetic, may lead to hyperglycaemia and diabetic ketoacidosis; conditions which are potentially lethal.

Hypoglycaemia

The time of occurrence of hypoglycaemia depends on the action profile of the insulins used and may, therefore, change when the treatment regimen is changed.

Conditions which may make the early warning symptoms of hypoglycaemia different or less pronounced include long duration of diabetes, intensified insulin therapy, diabetic nerve disease, medicinal products such as beta blockers or after transfer from animal‑source insulin to human insulin.

Adjustment of dose may be also necessary if patients undertake increased physical activity or change their usual meal plan. Exercise taken immediately after a meal may increase the risk of hypoglycaemia.

When compared with soluble human insulin, if hypoglycaemia occurs after an injection with rapid acting analogues, it may occur earlier.

Uncorrected hypoglycaemic or hyperglycaemic reactions can cause loss of consciousness, coma, or death.

Insulin requirements may be altered during illness or emotional disturbances.

Medication errors

Medication errors have been reported in which other insulins, particularly long-acting insulins, have been accidentally administered instead of insulin glulisine. Insulin label must always be checked before each injection to avoid medication errors between insulin glulisine and other insulins.

Continuous subcutaneous insulin infusion

Malfunction of the insulin pump or infusion set or handling errors can rapidly lead to hyperglycaemia, ketosis and diabetic ketoacidosis. Prompt identification and correction of the cause of hyperglycaemia or ketosis or diabetic ketoacidosis is necessary.

Cases of diabetic ketoacidosis have been reported when Apidra has been given in continuous subcutaneous insulin infusion in pump systems. Most of the cases were related to handling errors or pump system failure.

Interim subcutaneous injections with Apidra may be required. Patients using continuous subcutaneous insulin infusion pump therapy must be trained to administer insulin by injection and have alternative insulin delivery system available in case of pump system failure (see section 4.2 and 4.8).

Excipients

This medicinal product contains less than 1 mmol (23 mg) sodium per dose, i.e. it is essentially 'sodium‑free'.

Apidra contains metacresol, which may cause allergic reactions.

Combination of Apidra with pioglitazone

Cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for development of cardiac heart failure. This should be kept in mind if treatment with the combination of pioglitazone and Apidra is considered. If the combination is used, patients should be observed for signs and symptoms of heart failure, weight gain and oedema.

Pioglitazone should be discontinued if any deterioration in cardiac symptoms occurs.

4.5. Interaction with other medicinal products and other forms of interaction

Studies on pharmacokinetic interactions have not been performed. Based on empirical knowledge from similar medicinal products, clinically relevant pharmacokinetic interactions are unlikely to occur.

A number of substances affect glucose metabolism and may require dose adjustment of insulin glulisine and particularly close monitoring.

Substances that may enhance the blood‑glucose‑lowering activity and increase susceptibility to hypoglycaemia include oral antidiabetic medicinal products, angiotensin converting enzyme (ACE) inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors (MAOIs), pentoxifylline, propoxyphene, salicylates and sulphonamide antibiotics.

Substances that may reduce the blood‑glucose‑lowering activity include corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid, phenothiazine derivatives, somatropin, sympathomimetic medicinal products (e.g. epinephrine [adrenaline], salbutamol, terbutaline), thyroid hormones, oestrogens, progestins (e.g. in oral contraceptives), protease inhibitors and atypical antipsychotic medicinal products (e.g. olanzapine and clozapine).

Beta‑blockers, clonidine, lithium salts or alcohol may either potentiate or weaken the blood‑glucose‑lowering activity of insulin. Pentamidine may cause hypoglycaemia, which may sometimes be followed by hyperglycaemia.

In addition, under the influence of sympatholytic medicinal products such as beta‑blockers, clonidine, guanethidine and reserpine, the signs of adrenergic counter-regulation may be reduced or absent.

4.6. Pregnancy and lactation

Pregnancy

There are no or limited amount of data (less than 300 pregnancy outcomes) from the use of insulin glulisine in pregnant women.

Animal reproduction studies have not revealed any differences between insulin glulisine and human insulin regarding pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3).

Caution should be exercised when prescribing to pregnant women. Careful monitoring of glucose control is essential.

It is essential for patients with pre‑existing or gestational diabetes to maintain good metabolic control throughout pregnancy. Insulin requirements may decrease during the first trimester and generally increase during the second and third trimesters. Immediately after delivery, insulin requirements decline rapidly.

Breast-feeding

It is unknown whether insulin glulisine is excreted in human milk, but in general insulin does not pass into breast milk and is not absorbed after oral administration.

Breast‑feeding mothers may require adjustments in insulin dose and diet.

Fertility

Animal reproduction studies with insulin glulisine have not revealed any adverse effects on fertility.

4.7. Effects on ability to drive and use machines

The patient's ability to concentrate and react may be impaired as a result of hypoglycaemia or hyperglycaemia or, for example, as a result of visual impairment. This may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operating machines).

Patients should be advised to take precautions to avoid hypoglycaemia whilst driving. This is particularly important in those who have reduced or absent awareness of the warning symptoms of hypoglycaemia or have frequent episodes of hypoglycaemia. The advisability of driving should be considered in these circumstances.

4.8. Undesirable effects

Summary of the safety profile

Hypoglycaemia, the most frequent adverse reaction of insulin therapy, may occur if the insulin dose is too high in relation to the insulin requirement.

Tabulated list of adverse reactions

The following related adverse reactions from clinical studies were listed below by system organ class and in order of decreasing incidence (very common: ≥1/10; common: ≥1/100 to <1/10; uncommon: ≥1/1,000 to <1/100; rare: ≥1/10,000 to <1/1,000; very rare: <1/10,000), not known (cannot be estimated from the available data).

Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

MedDRA Organ system classes

Very common

Common

Uncommon

Rare

Not known

Metabolism and nutrition disorders

Hypoglycaemia

Hyperglycaemia (potentially leading to Diabetic ketoacidosis(1))

Skin and subcutaneous tissue disorders

Injection site reactions

Local hypersensitivity reactions

Lipodystrophy

Cutaneous amyloidosis

General disorders and administration site conditions

Systemic hypersensitivity reactions

(1) Apidra 100 Units/ml solution for injection in a vial: Most of the cases were related to handling errors or pump system failure when Apidra was used with CSII.

Description of selected adverse reactions

• Metabolism and nutrition disorders

Symptoms of hypoglycaemia usually occur suddenly. They may include cold sweats, cool pale skin, fatigue, nervousness or tremor, anxiousness, unusual tiredness or weakness, confusion, difficulty in concentration, drowsiness, excessive hunger, vision changes, headache, nausea and palpitation. Hypoglycaemia can become severe and may lead to unconsciousness and/or convulsions and may result in temporary or permanent impairment of brain function or even death.

Cases of hyperglycaemia have been reported with Apidra when used with CSII (see section 4.4) that has led to Diabetic Ketoacidosis (DKA); most of the cases were related to handling errors or pump system failure. The patient should always follow the Apidra specific instructions and always have access to alternative insulin delivery system in case of pump system failure.

• Skin and subcutaneous tissue disorders

Local hypersensitivity reactions (redness, swelling and itching at the injection site) may occur during treatment with insulin. These reactions are usually transitory and normally they disappear during continued treatment.

Lipodystrophy and cutaneous amyloidosis may occur at the injection site and delay local insulin absorption. Continuous rotation of the injection site within the given injection area may help to reduce or prevent these reactions (see section 4.4).

• General disorders and administration site conditions

Systemic hypersensitivity reactions may include urticaria, chest tightness, dyspnoea, allergic dermatitis and pruritus. Severe cases of generalized allergy, including anaphylactic reaction, may be life‑threatening.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9. Overdose

Symptoms

Hypoglycaemia may occur as a result of an excess of insulin activity relative to food intake and energy expenditure.

There are no specific data available concerning overdoses with insulin glulisine. However, hypoglycaemia may develop over sequential stages.

Management

Mild hypoglycaemic episodes can be treated by oral administration of glucose or sugary products. It is therefore recommended that the diabetic patient constantly carries some sugar lumps, sweets, biscuits or sugary fruit juice.

Severe hypoglycaemic episodes, where the patient has become unconscious, can be treated by glucagon or by glucose given intravenously by a healthcare professional. Glucose must also be given intravenously, if the patient does not respond to glucagon within 10 to 15 minutes.

Upon regaining consciousness, administration of oral carbohydrate is recommended for the patient in order to prevent relapse.

After treatment with glucagon, the patient should be monitored in a hospital in order to find the reason for this severe hypoglycaemia and prevent other similar episodes.

💬 Ask about this leaflet

Ask anything about Apidra 100 Units/ml solution for injection in a vial. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →